Trials / Completed
CompletedNCT03062254
Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 Therapy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- Sir Mortimer B. Davis - Jewish General Hospital · Academic / Other
- Sex
- Male
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
Broadly, the objective of this study is to evaluate the fractional decline of intensity of tracer uptake measured by SUVmax on 68Ga-PSMA PET/CT in bone metastases from prostate cancer following treatment with radium-223 as a surrogate marker for tumor cell killing.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | radium-223 dichloride | 6 doses of Radium-223 |
Timeline
- Start date
- 2018-03-22
- Primary completion
- 2020-07-15
- Completion
- 2021-07-15
- First posted
- 2017-02-23
- Last updated
- 2021-09-21
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT03062254. Inclusion in this directory is not an endorsement.